In a relief to FMCG major Dabur, two of its foreign subsidiaries, Dabur International and Dermoviva Skin Essentials, have been removed as a defendant in multiple lawsuits filed in a US court over allegations that their hair-relaxer products caused ovarian cancer, uterine cancer and other related health issues. However, lawsuits filed against its third international subsidiary Namaste Laboratories LLC, would continue before the US District Court for the Northern District of Illinois, according to a statement from Dabur on Wednesday. Dabur International and Dermoviva were removed and got relief in the multiple suits due to lack of jurisdiction as they have not either manufactured, marketed, distributed or sold hair relaxer products in the US, it added.
Evidently on the strength of continuing information provided by Lashkar-e-Tayiba operative and Pakistani American David Coleman Headley alias Daood Gilani, who was an integral protagonist in the conspiracy that led to the horrific 26/11 Mumbai terror attacks, four new Lashkar handlers of Headley have been chargesheeted in the US District Court for the Northern District of Illinois (Chicago).
Judge Harry Leinenweber at the US district court for the northern district of Illinois, eastern division, in a ruling denied Rana's motions for a new trial and for a judgment of acquittal. In two different orders on June 7 and 8, Leinenweber also scheduled his sentencing for December 4. However, no sentencing has been scheduled for his co-defendant David Headley
Pakistani-American LeT operative David Coleman Headley on Wednesday pleaded not guilty to the 12 counts filed against him in the superseding indictment returned on January 14, including charges he conspired in plotting the terror attacks in Mumbai and a Danish newspaper.
Rana, 59, a childhood friend of David Coleman Headley, was recently released from jail on compassionate ground after he told a US court that he has tested positive for the COVID-19.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances